
MVRBF
Healthcare · Biotechnology · $45.8M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 14, 2023 | After the close | -0.28 | -0.32 | -14.3% |
| Nov 2, 2022 | After the close | -0.49 | -0.27 | +44.9% |
| Aug 18, 2022 | After the close | -0.50 | -0.42 | +16.0% |
| Apr 27, 2022 | After the close | -0.37 | -0.59 | -59.5% |
| Feb 14, 2022 | After the close | -0.33 | -0.44 | -33.3% |
| Nov 2, 2021 | After the close | -0.18 | -0.26 | -44.4% |
| Aug 18, 2021 | After the close | -0.45 | -0.35 | +22.2% |
| Apr 27, 2021 | After the close | -0.55 | -0.18 | +67.3% |
| Feb 25, 2021 | After the close | -1.03 | -0.46 | +55.3% |
| Nov 9, 2020 | After the close | -0.59 | 0.16 | +127.1% |
| Aug 19, 2020 | After the close | -0.93 | -0.43 | +53.8% |
| May 4, 2020 | After the close | -1.02 | -0.79 | +22.5% |
| Feb 12, 2020 | After the close | -0.75 |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the…
| -1.08 |
| -44.0% |
| Nov 27, 2019 | Time not confirmed | -0.88 | -0.78 | +11.4% |
| Aug 28, 2019 | Before the open | -2.01 | -0.42 | +79.1% |
| May 2, 2019 | After the close | — | -0.06 | — |
| Feb 13, 2019 | After the close | — | -0.25 | — |
| Oct 25, 2018 | After the close | — | -0.53 | — |
| Jul 24, 2018 | After the close | — | -0.33 | — |
| Apr 26, 2018 | After the close | — | -0.42 | — |
| Feb 14, 2018 | Before the open | -3.60 | -5.08 | -41.1% |